CONDYDAV: A multicentre observational study of patients presenting external genital warts in France

Background - Since 2007 in France, human papilloma virus (HPV) vaccination has been licensed for use as a vaccine against HPV 6, 11, 16 and 18. The impact on the epidemiology of external genital warts (EGWs) in a large population remains unclear. Objectives. - To determine epidemiologic and clinical features of patients presenting EGWs in France in the era of HPV vaccination. Patients and methods - In this prospective, observational study, we analyzed clinical features and treatments between January 1st, 2012 and March 31, 2012 for patients consulting for EGWs at 15 STI clinics throughout France. Results. - A total of 372 men and 111 women were included; mean age 31.2 years. The women were younger than the men (31.7 and 28.9 years respectively P< 0.05). Among the patients, 416 (85.7%) were heterosexual, 13 bisexual and 54 (11.2%) homosexual, including one female. Males reported more sexual partners in the last 12 months (more than 3 partners in 32.6% versus 11.9%, P< 0.01). Among the men, 230 had involvement of the penis alone and 46 had involvement of the anus alone. Seventy-six patients had EGWs of the anus, and of these 26 were MSM. In females, 76 had an infection of the vulva alone and 22 co-infection of the vulva and anus. MSM and females were at higher risk than heterosexual males for anal involvement (P < 0.0001 and P =0.004, respectively). Three women had been vaccinated: two with GardasiP and one with Cervarix'. Cryotherapy was the preferred treatment. Conclusion.- With the advent of HPV vaccination, a global strategy for the prevention and treatment of EGW should be implemented. (C) 2016 Elsevier Masson SAS. All rights reserved.